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Streptokinase and urokinase have proved to be useful
in a limited number of clinical conditions. Mainly be-
cause of the risk and unpredictability of bleeding with
this first generation of thrombolytic agents, thrombolysis
has not been ingrained in medical practice. In the in-
terim, more fibrin-specific thrombolytic agents have been
developed such as acylated streptokinase-human plas-
minogen complex, tissue-type plasminogen activator
(t-PA) and single chain urokinase-type plasminogen ac-
tivator (scu-PA or pro-urokinase). Only the latter two
drugs do not induce major systemic fibrinogenolysis at
thrombolytic effective doses. These two agents, obtained
The principal aim of thrombolytic therapy is the removal
of a pathologic intraluminal thrombus or embolus that has
not been dissolved by spontaneous fibrinolysis. In certain
clinical conditions such as acute myocardial infarction, the
speed of thrombus dissolution is critical because only early
reperfusion can reduce the infarct size and improve jeop-
ardized left ventricular function. The same concern for rapid
lysis of emboli prevails in life-threatening, massive pul-
monary embolism. Although direct local delivery of throm-
bolytic agents at the site of the vascular occlusion may
enhance its lysis, there is an inherent time lag required for
coronary and pulmonary artery catheterization with its un-
avoidable delay in drug administration (I).
Regardless of whether systemic or regional administra-
tion is selected, thrombolytic treatment should be safe.
Bleeding complications are the main reason why strepto-
kinase and urokinase have not been ingrained in medical
practice. The novel, more fibrin-specific thrombolytic agents
tissue-type plasminogen activator (t-PA) and pro-urokinase
(now termed single chain urokinase-type plasminogen ac-
tivator [scu-PA]) are more promising in this regard. The
latter drugs are also easier to use because, at effective throm-
bolytic doses. no or only limited systemic fibrinolytic ac-
tivation occurs, avoiding the undesirable breakdown of the
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by recombinant techniques, as well as acylated strep-
tokinase-plasminogen complex are available for clinical
investigations.
The first results of systemic administration of recom-
binant tissue-type plasminogen activation (t-PA) in pa-
tients with acute myocardial infarction were published
and are promising. Continued experimentation with
t-PA and pro-urokinase in evolving myocardial infarc-
tion and other thrombotic disorders is essential to better
delineate their therapeutic index.
(J Am Coil Cardiol1986;8:33B-40B)
hemostatic system and eliminating the need for laboratory
monitoring.
Streptokinase
Streptokinase is a nonenzymatic protein isolated from the
broth of Lancefield group C strains of beta-hemolytic strep-
tococci. It is a single polypeptide chain without carbo-
hydrates, with a molecular weight of 47 kilodaltons (2).
The amino acid sequence of streptokinase is known and is
similar to that of streptomyces griseus and human trypsin
(3,4).
Streptokinase is an indirect activator of plasminogen. It
initially forms a I: 1 stoichiometric complex with the zy-
mogen plasminogen, which thereby undergoes a transition,
allowing exposure of the active site within plasminogen
without apparent peptide bond cleavage (5-8). This mod-
ified streptokinase-plasminogen complex behaves as a plas-
minogen activator (9). The activator complex can also in-
duce a limited proteolysis in the plasminogen molecule of
other streptokinase-plasminogen molecules whereby plas-
minogen is converted to plasmin; streptokinase progres-
sively degrades to smaller fragments, resulting in a gradual
loss of activator activity (10-12).
Mode of action. After the injection of indium-l 3I-labeled
streptokinase, an immediate rapid clearance phase (half-life
18 minutes) is followed by a slower disappearance phase
(half-life 83 minutes) (13). The initial rapid phase is inter-
preted as immune complexing of streptokinase. Indeed, hu-
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man plasma contains antibodies directed against streptoki-
nase, probably as a result of previous infections with beta-
hemolytic streptococci. The titer of streptokinase antibodies
varies from person to person (14). Because streptokinase
reacts with antibodies and is thereby rendered biochemically
inert, sufficient amounts of streptokinase must be infused
to neutralize the antibodies before fibrinolytic activation is
obtained (15). If a loading dose of streptokinase high enough
to overcome the streptococcal antibodies is given, plasmin-
ogen will be activated to plasmin. Low doses of strepto-
kinase may generate more plasmin and less streptokinase-
plasminogen complex; however, the plasmin formed will
soon be neutralized by circulating antiplasmin. Only when
the 0'2-antiplasmin level is markedly reduced will plasmin
be less rapidly neutralized and exert a proteolytic effect on
several plasma proteins, among which the coagulation com-
ponents fibrinogen and factors V and VIII are the most
important.
A high initial dose of streptokinase will be associated
with a rapid and profound reduction in the level of circu-
lating plasminogen, antiplasmin and fibrinogen (14). Pro-
vided a high maintenance dose of streptokinase follows,
high circulating activator levels are obtained and fibrinogen
levels start to rise in the subsequent 24 hours (16).
Excessive lowering of the concentrations of these blood
coagulation components in plasma, combined with the in-
hibitory effect of some fibrinogen degradation products on
platelet aggregation and fibrinogen polymerization, are con-
sidered responsible for the potentially dangerous bleeding
tendency (17-19). However, the magnitude of systemic fi-
brinogenolysis and its laboratory derangements do not strictly
correlate with bleeding manifestations (20-22).
Equimolar Streptokinase-Plasminogen
Complex and Its Stable Acyl Derivatives
Equimolar complexes of streptokinase and human plas-
minogen have been used for thrombolysis because their
fibrinolytic activity does not depend on the circulating plas-
minogen content (23,24) and also because the plasminogen
conformation is somewhat changed in the complex, result-
ing in a better catalytic activity (25).
Clinical application. The clinical use of this complex
was attempted after a favorable report (26) of the sequential
intravenous use of 90- I20 mg of human Lys-plasminogen,
followed by 600,000 IU of streptokinase. With 100,000
IU/h of equimolar streptokinase-plasminogen complex, ad-
ministered in a continuous infusion over 2 days, the residual
plasminogen remained between 10 to 20% of the normal
value while the fibrinogen levels decreased by two-thirds
(27). These investigations were conducted in patients with
up to 6 week old thrombotic occlusions of the femoropop-
liteal artery, of which 73% were cleared. However, serious
cerebrovascular side effects were encountered.
The hope that the streptokinase-plasminogen complex
would not be immunogenic in human patients could not be
substantiated (28). Clinical experience with equimolar mix-
tures of streptokinase and human plasminogen is limited,
and streptokinase-plasmin beta-chain complexes are almost
nonexistent (29). It should be noted that the lysine binding
sites of plasminogen responsible for its binding to fibrin are
located in the alpha-chain, theoretically rendering a plasmin
beta-chain-streptokinase complex less fibrin-specific.
Acyl derivatives. Stable acyl derivatives of an equimolar
streptokinase-plasminogen complex have been prepared by
acylation of the Ser 740 residue located in the catalytic
center of the light beta-chain of plasminogen (30,31). Be-
cause the catalytic center is functionally separate from its
fibrin-binding site located in the heavy or alpha-chain of
plasmin, acylated streptokinase-human plasminogen is cat-
alytically inert so that it can circulate in the vascular system
without reaction with either plasma inhibitors or plasmin-
ogen, but still bind to fibrin through the unmodified kringle
domains of the plasminogen moiety. These compounds de-
acylate under physiologic conditions after first order kinet-
ics, with half-lives of 40 minutes (p-anisoyl derivative, BRL-
26921) and 17 hours (p-aminobenzoyl derivative, BRL-
33575).
In a thrombosis model in the rabbit, acylated streptoki-
nase-plasminogen was significantly more thrombolytic than
the unmodified streptokinase-plasminogen complex, both
given as bolus doses (31). In a jugular vein thrombosis
model in dogs, streptokinase-plasminogen results in a marked
decrease to 20% of the original fibrinogen level at a dose
that is not yet thrombolytic, while the two acylated com-
pounds used at equivalent streptokinase doses were throm-
bolytic but also markedly reduced the fibrinogen level (32,33).
In human volunteers, 5 mg of the BRL-26921 compound
had little effect on the systemic fibrinolytic system; on a
molar basis, this dose is equivalent to 178,000 IU of strep-
tokinase and does produce a significant decrease in fibrin-
ogen and plasminogen (34). At doses greater than 5 mg,
progressive reductions were observed in plasma levels of
fibrinogen, plasminogen and O'-antiplasmin (35).
Clinical application. The clinical indication for which
acylated streptokinase-plasminogen complexes have been
best studied is acute myocardial infarction. With an intra-
coronary bolus injection of 10 mg or more of BRL 26921,
angiographically determined reperfusion rates of 75% were
obtained in 74 patients (36). After intravenous bolus injec-
tion of 30 mg of BRL 26921, coronary reperfusion was
achieved in 86% of 57 patients. Several minor bleeding
episodes were reported in most cases, and with the latter
dose, fibrinogen levels were reduced by as much as 80%
of the preinfusion value (37). Other side effects were those
usually observed after streptokinase. The main advantage
of acylated streptokinase-plasminogen complexes seems to
be that they can be given as an intravenous bolus injection.
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Urokinase
The presence of a fibrinolytic activity in urine was dis-
covered in 1913 by Johansson (38). Much later, it was found
that the urine activates plasminogen (39); the plasminogen-
converting principle was recognized as a kinase, hence the
name urokinase (4). Because this term is a misnomer, the
Subcommittee on Fibrinolysis (41) recommends the des-
ignation two-chain urokinase-type plasminogen activator.
Urokinase has been isolated and purified from human urine
(42) and later from cultured human embryonic kidney cells
(43) and certain tumor cells (44). The gene coding for uro-
kinase has been cloned and expressed in Escherichia coli
(45).
Urokinase is a trypsin-like serine protease composed of
two polypeptide chains (20 and 30 kilodaltons) connected
by a single disulfide bridge. Urokinase may occur in two
molecular forms: a high molecular weight form (54 kilo-
daltons) and its proteolytic product or a low molecular weight
form (31 kilodaltons) that contains mainly the heavy chain
(the high molecular weight form apparently predominates
in humans) (46). The complete primary structure of uro-
kinase has been elucidated (47); the heavy and light chains
contain, respectively, 253 and 157 amino acids.
Mode of action. In contrast to streptokinase, urokinase
is a direct activator of plasminogen and cleaves, by first-
order kinetics, a single Arg 560-Val 561 bound in the plas-
minogen molecule (9). Although in vitro high molecular
weight urokinase has greater clot-dissolving activity than
does the low molecular weight form (48), this difference
could not be confirmed in vivo (49). Urokinase prepared
from either urine or tissue culture is not antigenic in humans
(50), and both have a similar esterase and fibrinolytic ac-
tivity in vitro and in vivo (49,51).
Urokinase differs from tissue-type plasminogen activator
both in its antigenic characteristics and in its enzyme spec-
ificity, particularly with respect to the activation of fibrin-
associated plasminogen (52,53). The mean clearance half-
life of urokinase in humans is 14 ± 6 minutes (54). From
subsequent turnover studies of urokinase in rabbits (55,56)
and squirrel monkeys (56), it was concluded that urokinase
is rapidly removed from the blood by clearance and deg-
radation in the liver. Recognition by the liver does not
require a functional active site and is not mediated through
carbohydrate side chains. Inactivation by plasma protease
inhibitors (aTantiplasmin, aTmacroglobulin, a}-antitryp-
sin and antithrombin III) does not seem to playa significant
role in the inhibition of urokinase in vivo (57-60). However,
urokinase antigenic protein has been detected in human plasma
(61,62) and more recently, evidence has been presented for
a new fast-acting inhibitor of urokinase (and of t-PA) in
very low concentrations in the blood (63).
Clinical applications. In most therapeutic trials a load-
ing dose of 2,500 to 4,500 Committee on Thrombolytic
Agents (CTA) units per kg body weight has been admin-
istered in a short (16 to 60 minutes) intravenous infusion,
followed by the same hourly maintenance dose for 12 to 24
hours. With this dose, a mild depletion of plasminogen and
fibrinogen is noted with marked fibrinolytic activity in cir-
culating plasma; higher doses reduce the plasminogen and
fibrinogen levels to a similar extent as streptokinase (49,54).
A multicenter study (64) in patients with recent pulmo-
nary embolism has compared a short 12 hour treatment with
4,400 CTA units of urokinase/kg per h and a 24 hour treat-
ment with 2,000 CTA units/kg per h together with heparin.
There was no significant difference between the two regi-
mens in the changes seen in the pulmonary angiogram.
Bleeding complications were also the same with the two
treatments, as was the incidence of recurrent embolism oc-
curring within 24 hours of stopping thrombolytic treatment.
A multicenter trial (65) was conducted in France to compare
the 12 hour treatment with 4,400 CTA units of urokinase/
kg per hour and the 24 hour treatment with half this hourly
dose in patients with recent pulmonary embolism. The an-
giographic results and bleeding complications were not sig-
nificantly different between the two regimens. However,
either treatment tested would be too short to dissolve con-
comitant deep vein thrombi effectively, which requires 4 to
5 days of intense thrombolysis. The best prevention of re-
current pulmonary embolism is, indeed, complete phlebo-
graphic clearance of deep vein thrombosis (66,67).
Tissue-Type Plasminogen Activator
Structure. Tissue-type plasminogen activator (t-PA) has
been isolated and purified from human uterine tissue (68)
and a human melanoma cell line (Bowes, RPMI-7272) (69);
more recently, the gene for human t-PA has been cloned
and recombinant t-PA expressed (70). Tissue-type plasmin-
ogen activator is a serine protease with a molecular weight
of approximately 70 kilodaltons; t-PA obtained from Bowes
melanoma cells appears to exist in two variants with an
apparent molecular weight difference of 3 kilodaltons (71,72).
The concentration oft-PA in human plasma is approximately
5 ng/ml (circa 0.1 nM). Human t-PA consists of one poly-
peptide chain containing 527 amino acids, exhibiting serine
as the NH} terminal amino acid (70). After limited plasmic
action, the molecule is converted to a two-chain activator
linked by disulfide bonds (69,73,74). This occurs by cleav-
age of the Arg 275-I1e 276 peptide bond, yielding a heavy
chain (36 kilodaltons) derived from the NH} terminal part
of the molecule and a light chain (32 kilodaltons) comprising
the COOH terminal region. The heavy chain contains two
regions that share a high degree of homology with the five
kringles in plasminogen and with the single kringle in uro-
kinase. The molecule contains an NH2 terminal region that
is homologous with the finger domains responsible for the
fibrin affinity of fibronectin (75) and another sequence hav-
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ing homology with human epidermal growth factor. The
catalytic site is located in the light or beta-chain of t-PA; it
contains the three residues common to all trypsin-like serine
proteases (histidine in position 325, aspartic acid in position
374 and serine in position 481) and is highly homologous
to corresponding parts of trypsin, thrombin, plasmin and
elastase (70,76). The major differences among the mam-
malian serine proteases occur in exposed areas and external
loops (77,78).
Mechanism of action. Purified tissue-type plasminogen
activator (t-PA) binds specifically to fibrin (79-82) or cyan-
ogen bromide (CNBr)-digested fibrinogen fragments (83).
Quantitative data have been obtained on t-PA binding to
fibrin and on the role of fibrin in the activation of plasmin-
ogen by t-PA (54,84,85). It was shown that t-PA has a weak
affinity for plasminogen (Km = 65 pM) in the absence of
either solid phase fibrin or a CNBr-digested fibrinogen, but
a much higher affinity when fibrin is present (Km = 0.16
JLM). Kinetic data support a mechanism is which t-PA and
plasminogen adsorb to a fibrin clot in a sequential and or-
dered way, yielding a ternary complex (54).
No difference was found in these kinetic variables for
either the t-PA of melanoma origin (69) or that obtained by
recombinant DNA technology (70). The structures involved
in the binding of t-PA to fibrin are not clearly defined. The
NH2 terminal region of t-PA, which is homologous to the
finger region of fibronectin, has been implicated (75), but
recent observations seem to be at variance with this hy-
pothesis (86). On the fibrin surface, light chain t-PA is
quickly converted to a two-chain form during fibrinolysis,
but there is no evidence that this conversion plays a role in
the regulation of fibrinolysis (87).
This increased affinity appears to be the result of a "sur-
face assembly" of t-PA and plasminogen on the fibrin sur-
face. Fibrin essentially increases the local plasminogen con-
centration, creating an additional interaction between t-PA
and its substrate through a cyclic fibrin bridge and resulting
in a low Michaelis-Menten constant for the activation of
plasminogen by t-PA (54). Plasmin formed on the fibrin
surface has both its lysine-binding sites and active sites
occupied and is, thus, only slowly inactivated by lXTanti-
plasmin (half-life = 10 seconds). Liberated plasmin is, how-
ever, very quickly inactivated by lXTantiplasmin (half life
= 100 ms). Effective thrombus dissolution in vivo, thus,
requires a continuous replacement at the fibrin surface of
neutralized plasmin by new plasminogen molecules.
The one-chain and two-chain forms of t-PA have differ-
ent amidolytic activities toward low molecular weight
substrates (88). They have, however, virtually the same fi-
brinolytic activity in a purified system, and the plasmin-
ogen-activating properties are also similar (74,87). Several
laboratories have obtained evidence for the existence of a
rapid-acting inhibitor (or inhibitors) of t-PA at low concen-
trations in plasma of healthy individuals (89-92) or at higher
levels in pathologic plasma samples (93-95). The complex
formed between t-PA and its specific inhibitor has a molec-
ular weight of 110 kilodaltons and is formed very rapidly
(second order rate constant 107 M-1s- 1 (96).
Clinical effects. Pharmacokinetic studies in human vol-
unteers (96a) and patients with myocardial infarction (97)
have shown two compartment behavior of t-PA, with a
disappearance from plasma with alpha-phase half-life of 5.7
minutes, a half-life of 1.3 hours and a total clearance of
380 mllmin. Experience with t-PA is limited to about 500
patients with acute myocardial infarction (98-103). With
the doses used, a decrease in fibrinogen concentration to
about 50% of the preinfusion value was noted. It was shown
that systemic activation of the fibrinolytic system is depen-
dent on the dose and infusion rate, as could be anticipated
from the kinetic variables of the activation of plasminogen
by t-PA (105). This fibrinogen decrease might be due, in
part, to in vitro fibrinogen degradation. It was noted (103)
that the fibrinogen level also decreased in the placebo-treated
patients by 11 %, indicating that coronary catheterization
and hemodilution could also be partly responsible. Both
hematoma at the catheter site and prolonged bleeding at
puncture sites were half as frequent during t-PA treatment
compared with streptokinase treatment in a comparative trial
(102). Further experience is required to substantiate whether
less bleeding is encountered when using t-PA for therapeutic
thrombolysis as compared with streptokinase or urokinase.
It was noted in the two European trials with t-PA (102,103)
that the observed increase in fibrinogen degradation products
is less than anticipated from the reduction of circulating
fibrinogen (104,105). It is possible that the fibrinogenolytic
breakdown is limited to the generation of the early degra-
dation products, fragments X or Y, or both, which are
slowly coagulable or incorporated in fibrin clots. This hy-
pothesis is further supported by the less substantial decrease
in fibrinogen during t-PA treatment when measured by the
sodium sulphite precipitation method (106), which assesses
both the fibrinogen and fragments X and Y, rather than with
a coagulation rate assay (107).
Single Chain Urokinase-Type Plasminogen
Activator (scu-PA) or Pro-Urokinase
Several groups (l08-114) have reported the isolation of
an inactive single chain precursor of urokinase that, after
selective cleavage of the Lys 158-Ile 159 peptide bond by
plasmin, is converted to a fully active two-chain structure.
This single chain precursor of urokinase is, however, a true
enzyme (115).
Mechanism of action. The mechanism for the activation
of plasminogen by scu-PA has been recently elucidated (116);
JACC Vol 8, No 6
December 1986.33B-40B
VERSTRAETE AND COLLEN
PHARMACOLOGY OF THROMBOLYTIC DRUGS
37B
scu-PA directly activates plasminogen to plasmin, The gen-
erated plasmin then converts scu-PA to urokinase, which in
tum activates plasminogen to plasmin, In a plasma milieu,
activation of plasminogen by scu-PA is prevented by com-
petitive inhibition.
A detailed kinetic analysis (116) revealed that scu-PA is
an equally potent activator of plasminogen as urokinase,
This is due to the fact that the proenzyme, which is virtually
inactive toward low molecular weight substrates for uro-
kinase, forms an intermediate of the Michaelis-Menten type
with plasminogen, with a much higher affinity than that of
the active enzyme with its substrate (117).
A urokinase-type plasminogen activator can be purified
from conditioned media of several human cell cultures, par-
ticularly from the human lung adenocarcinoma line CALU-
3 (119). This material is kinetically identical to scu-PA. In
human urine, the urokinase-related proteins consist of about
25% of scu-PA (10 to 20 /Lg/liter) and of about 75% two-
chain urokinase (40 to 50 /Lg/liter), the bulk of which is
complexed to an inhibitor (118).
The gene coding for urokinase has recently been cloned
and expressed in E, coli (45). However, if proteolytic deg-
radation is carefully avoided during purification, scu-PA
may be obtained from the same expression system (114).
Natural and recombinant scu-PA can induce more c1ot-
selective thrombolysis than can natural or recombinant uro-
kinase in experimental thrombotic models (60, 111 ,119, 120).
Thrombolytic effects. Coronary thrombolysis was ob-
tained after intravenous infusion of scu-PA in dogs (111)
and baboons (Flameng et aI., unpublished observations,
1986). This thrombolytic effect, obtained after 23 ± 2
minutes in four dogs and 21 ± 4 minutes in six baboons,
was not associated with systemic fibrinolytic activation.
Scu-PA was administered to six patients with evolving
myocardial infarction of less than 5 hours' duration and
angiographically confirmed total occlusion of the infarct-
related coronary artery (I 20a) , In four of the six patients,
complete reperfusion was obtained during intravenous in-
fusion and in one patient after 20 minutes of intracoronary
infusion; one patient did not respond. The infusion caused
significant changes in the fibrinogen level and generation
of breakdown products in one of the six patients only.
A marked synergism between t-PA and scu-PA and be-
tween t-PA and urokinase was recently discovered (Collen
et aI., unpublished observations, 1986) in rabbits with an
experimental juglar vein thrombosis. The simultaneous in-
fusion of the drug combination had an equivalent throm-
bolytic effect at one-fifth of the dose compared with the
separate infusion of either agent. No clear synergism was
observed between scu-PA and urokinase. Provided the pres-
ent observation can be extrapolated to human patients, the
combined use of synergic thrombolytic agents may allow
not only significant reduction of the total doses, but also
eliminate the systemic fibrinolytic activation and its unde-
sirable breakdown of the hemostatic system.
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